NEW YORK, May 1, 2024 /PRNewswire/ -- Traverse Biotech, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. This grant will support the development of our oral innate immunotherapy stimulant modality with an emphasis on the evaluation of monocytic cellular activation using pathogen-associated molecular patterns (PAMPs) motifs..

2024年5月1日，纽约/PRNewswire/--Traverse Biotech，Inc.获得了美国国立卫生研究院过敏与传染病研究所（NIAID）的第一阶段小企业创新研究（SBIR）资助。该赠款将支持我们的口服先天免疫疗法兴奋剂模式的发展，重点是使用病原体相关分子模式（PAMPs）基序评估单核细胞活化。。

Brandy Houser, co-Founder and CEO of Traverse Biotech, expressed: 'We are grateful for the support of NIAID. We believe that our product candidate has broad applicability to several immunological pathologies where myeloid derived cells are dysfunctional and ultimately not effective in disease resolution.'.

Traverse Biotech联合创始人兼首席执行官布兰迪·豪斯（BrandyHouser）表示：“我们感谢NIAID的支持。我们相信，我们的候选产品广泛适用于骨髓来源细胞功能失调且最终无法有效解决疾病的几种免疫病理。”。

This work will be conducted in collaboration with Dr. Sara Lustigman, Head of Molecular Parasitology at Lindsley F. Kimball Research Institute of New York Blood Center Enterprises. Dr. Lustigman's extensive academic research in immunology and infectious diseases will enable the evaluation of Traverse's innate immune stimulator mechanism of action in validated preclinical pathogenic models..

这项工作将与纽约血液中心企业Lindsley F.Kimball研究所分子寄生虫学负责人Sara Lustigman博士合作进行。Lustigman博士在免疫学和传染病方面的广泛学术研究将有助于在经过验证的临床前致病模型中评估Traverse的先天免疫刺激作用机制。。

About Traverse Biotech, Inc. is a privately held US biotechnology company that develops innovative immunotherapy products. Traverse Biotech focuses on late-stage preclinical and early clinical development of product candidates derived from de-risked technology platforms. For each product within its pipeline, Traverse licenses worldwide commercialization rights from selected international biopharma companies that are divesting promising product candidates due to strategic portfolio rationalization.

关于Traverse Biotech，Inc.是一家美国私营生物技术公司，开发创新的免疫治疗产品。Traverse Biotech专注于从无风险技术平台衍生的候选产品的晚期临床前和早期临床开发。对于其管道内的每种产品，Traverse从选定的国际生物制药公司获得全球商业化权利许可，这些公司由于战略投资组合合理化而正在剥离有前途的候选产品。

Via an original partnership model, Traverse Biotech accelerates therapeutic development of each asset through clinical proof-of-concept. Its flexible and lean operating structure enables rapid clinical evaluation and cost reduction around all aspects of product development reaching patients sooner..

通过最初的合作伙伴关系模型，Traverse Biotech通过临床概念验证加速了每种资产的治疗开发。其灵活而精益的操作结构能够快速进行临床评估，并围绕产品开发的各个方面降低成本，从而更快地到达患者手中。。

SOURCE Traverse Biotech

SOURCE Traverse Biotech公司